BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell
Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Hrain Biotechnology Co., Ltd. Shanghai Changzheng Hospital